Grafico Azioni Bayer (XE:BAYN)
2 Mesi : Da Dic 2019 a Feb 2020
By Kim Richters
Bayer AG (BAYN.XE) said Thursday that it has entered a research collaboration with pharma-tech company Exscientia Ltd. to use artificial intelligence in cardiovascular and oncology drug discovery.
The German pharmaceutical and chemical giant said the companies will focus on early-stage research and use artificial intelligence to predict potential drug molecules, possibly accelerating drug discovery.
"Exscientia's AI-driven drug discovery technology provides novel chemical matter for difficult-to-address targets and could identify novel drug candidates more efficiently through less optimization cycles," Bayer said.
As part of the three-year agreement, the U.K.-based Exscientia may get up to 240 million euros ($267.1 million) as well as sales royalties, while Bayer will own the rights to lead structures generated during the collaboration.
Write to Kim Richters at firstname.lastname@example.org
(END) Dow Jones Newswires
January 09, 2020 07:52 ET (12:52 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.